AU755350B2 - 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor - Google Patents

1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor Download PDF

Info

Publication number
AU755350B2
AU755350B2 AU85607/98A AU8560798A AU755350B2 AU 755350 B2 AU755350 B2 AU 755350B2 AU 85607/98 A AU85607/98 A AU 85607/98A AU 8560798 A AU8560798 A AU 8560798A AU 755350 B2 AU755350 B2 AU 755350B2
Authority
AU
Australia
Prior art keywords
group
substituted
aryl
naphthylidin
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU85607/98A
Other languages
English (en)
Other versions
AU8560798A (en
Inventor
Yasuhiro Hayashi
Hidekazu Inoue
Tetsuo Shimamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of AU8560798A publication Critical patent/AU8560798A/en
Application granted granted Critical
Publication of AU755350B2 publication Critical patent/AU755350B2/en
Assigned to DAIICHI SUNTORY PHARMA CO., LTD reassignment DAIICHI SUNTORY PHARMA CO., LTD Alteration of Name(s) in Register under S187 Assignors: SUNTORY LIMITED
Assigned to DAIICHI ASUBIO PHARMA CO., LTD. reassignment DAIICHI ASUBIO PHARMA CO., LTD. Request to Amend Deed and Register Assignors: DAIICHI SUNTORY PHARMA CO., LTD
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU85607/98A 1997-08-06 1998-08-06 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor Ceased AU755350B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21232297 1997-08-06
JP9-212322 1997-08-06
PCT/JP1998/003510 WO1999007704A1 (en) 1997-08-06 1998-08-06 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor

Publications (2)

Publication Number Publication Date
AU8560798A AU8560798A (en) 1999-03-01
AU755350B2 true AU755350B2 (en) 2002-12-12

Family

ID=16620631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85607/98A Ceased AU755350B2 (en) 1997-08-06 1998-08-06 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor

Country Status (8)

Country Link
US (2) US6297248B1 (zh)
EP (1) EP0958297A1 (zh)
KR (1) KR20000068711A (zh)
CN (1) CN1158281C (zh)
AU (1) AU755350B2 (zh)
CA (1) CA2268190A1 (zh)
HU (1) HUP0001054A3 (zh)
WO (1) WO1999007704A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038867A1 (fr) 1998-01-29 1999-08-05 Suntory Limited Derives de 1-cycloalkyle-1,8-naphthyridine-4-one presentant une activite inhibitrice de la phosphodiesterase iv
JP2002511460A (ja) * 1998-04-08 2002-04-16 ノバルティス アクチエンゲゼルシャフト 新規除草剤
AU3487500A (en) * 1999-02-08 2000-08-25 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001042244A1 (fr) * 1999-12-08 2001-06-14 Grelan Pharmaceutical Co., Ltd. Nouveaux derives 1,8-naphtyridin-2(1h)-one
JP2003529601A (ja) 2000-03-21 2003-10-07 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−オキソ−１，４−ジヒドロ［１，８］ナフチリジン−３−カルボキサミド
MXPA02009250A (es) 2000-03-21 2003-03-12 Upjohn Co 4-hidroxi-1,8-naftiridin--3-carboxamidas como agentes antivirales.
JP4460221B2 (ja) 2001-05-24 2010-05-12 メルク フロスト カナダ リミテツド １−ビアリール−１，８−ナフチリジン−４−オン系ホスホジエステラーゼ−４阻害薬
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
EP1716150B1 (en) * 2004-01-22 2008-04-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2534603T3 (es) * 2004-06-30 2015-04-24 E-L Management Corp. Composiciones cosméticas y procedimientos que comprenden Rhodiola Rosea
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
FR2873695A1 (fr) * 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
BRPI0514381A (pt) * 2004-07-30 2008-06-10 Palumed Sa compostos hìbridos de aminoquinolina-antibiótico, composições farmacêuticas, método de preparação e uso destes
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2721065C (en) 2008-05-27 2016-09-27 Astrazeneca Ab Phenoxypyridinylamide derivatives and their use as pde4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20210110623A (ko) 2018-12-28 2021-09-08 리제너론 파마슈티칼스 인코포레이티드 아라키도네이트15-리폭시게나제 (alox15) 억제제를 사용하는 호흡기 장애의 치료

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851535A (en) * 1985-01-23 1989-07-25 Toyama Chemical Co., Ltd. Nicotinic acid derivatives
WO1997004775A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
JPS55164682A (en) * 1979-06-11 1980-12-22 Yamanouchi Pharmaceut Co Ltd 1-alkyl-2-oxo-2h-1,8-naphthyridine derivative and its preparation
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
WO1994012499A1 (en) * 1992-12-01 1994-06-09 The Green Cross Corporation 1,8-naphthyridin-2-one derivative and use thereof_
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
MX9701600A (es) * 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
WO1996012704A1 (fr) * 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif
RU2177945C1 (ru) * 1995-09-22 2002-01-10 Вакунага Фармасьютикал КО., Лтд. Производное пиридонкарбоновой кислоты или его соль
PL332941A1 (en) 1996-10-30 1999-10-25 Bayer Ag Method of obtaining naphtyridinic compounds and novel intermediate compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851535A (en) * 1985-01-23 1989-07-25 Toyama Chemical Co., Ltd. Nicotinic acid derivatives
WO1997004775A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use

Also Published As

Publication number Publication date
CN1158281C (zh) 2004-07-21
WO1999007704A1 (en) 1999-02-18
CA2268190A1 (en) 1999-02-18
US6541480B2 (en) 2003-04-01
EP0958297A1 (en) 1999-11-24
CN1239478A (zh) 1999-12-22
AU8560798A (en) 1999-03-01
HUP0001054A2 (hu) 2000-10-28
HUP0001054A3 (en) 2001-01-29
US20020006935A1 (en) 2002-01-17
US6297248B1 (en) 2001-10-02
KR20000068711A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
AU755350B2 (en) 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase nhibitor
US7211572B2 (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7566784B2 (en) Bicyclic heterocycles as kinase inhibitors
US7547779B2 (en) Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
AU2008326784B2 (en) Non-nucleoside reverse transcriptase inhibitors
TWI426908B (zh) 特定化學品、組成物及方法
JP2001500153A (ja) 置換２―ピリミジンアミン類、それらの製造法およびそれらのタンパク質キナーゼ阻害剤としての使用
WO2005080330A1 (ja) ヘテロアリールフェニルウレア誘導体
JP2007507549A (ja) キナーゼ阻害剤としての１，６，７−三置換アザベンゾイミダゾールの調製
JP2002501051A (ja) 薬剤として有用なフェニルアラニン誘導体
JP5126830B2 (ja) ピロロ［３，２−ｃ］ピリジン誘導体及びその製造方法
JPWO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
SK27299A3 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
WO2002088122A1 (fr) Composes heterocycliques
AU2007296964B2 (en) Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
TW201925187A (zh) 經碸吡啶烷基醯胺取代之雜芳基化合物
PL175788B1 (pl) Amidowe pochodne indolu i zawierające je kompozycje farmaceutyczne
JP2011063516A (ja) アミド誘導体
TW574221B (en) Substituted 4-oxo-napthyridine-3-carboxamides; GABA brain receptor ligands
JP2006517976A (ja) 新規化合物
KR20020058091A (ko) 신규한 1,8-나프티리딘-2(1ｈ)-온 유도체
US5405964A (en) Imidazopyridines
JP3373838B2 (ja) ナフチリジン誘導体
JPH11106385A (ja) Ｉｖ型ホスホジエステラーゼ阻害作用を有する１−アリール−１，８−ナフチリジン−４−オン誘導体
JP2004115450A (ja) 医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DAIICHI SUNTORY PHARMA CO LTD

Free format text: FORMER OWNER WAS: SUNTORY LIMITED